Taken together, therefore, our results and those described above suggest that the selective blockade of PDE4 activity could be a promising therapeutic strategy for a myriad of vascular pathologies with an inflammatory component, from AAA to atherosclerosis restenosis and venous thrombosis [43,44,45,46]. Here, PDE4A is linked to triple-A syndrome.